Ligand id: 5742

Name: netupitant

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: netupitant

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 39.68
Molecular weight 578.25
XLogP 8.7
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Netupitant is approved as a component of the fixed-dose drug Akynzeo®, the other component being palonosetron. This orally administered drug mixture is a prophylactic used to provide supportive care for patients receiving emetogenic chemotherapy, and is superior in action to palonosetron alone [1].
In April 2018 the FDA approved a modified formulation of Akynzeo® that is designed for i.v. infusion, and contains fosnetupitant (phosphorylated netupitant; PubChem CID 71544786) in place of netupitant.
Mechanism Of Action and Pharmacodynamic Effects
Netupitant is an antagonist of the neurokinin type 1 receptor (NK1) and palonosetron is a serotonin 5-HT3 receptor antagonist. These compounds act together to inhibit pathways involved in emesis [1].
External links